

# Stefan D Anker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8775531/publications.pdf>

Version: 2024-02-01

314  
papers

52,067  
citations

6254

80  
h-index

1599

216  
g-index

317  
all docs

317  
docs citations

317  
times ranked

35312  
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 2129-2200.	2.2	13,008
2	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	2.2	5,558
3	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	27.0	2,821
4	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.	7.1	2,307
5	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	27.0	2,143
6	Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. <i>New England Journal of Medicine</i> , 2009, 361, 2436-2448.	27.0	1,633
7	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 2219-2229.	27.0	1,148
8	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	7.1	820
9	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. <i>Lancet</i> , The, 2020, 396, 819-829.	13.7	816
10	Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. <i>Lancet</i> , The, 2003, 361, 1077-1083.	13.7	648
11	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 2252-2263.	27.0	599
12	Iron deficiency: an ominous sign in patients with systolic chronic heart failure. <i>European Heart Journal</i> , 2010, 31, 1872-1880.	2.2	515
13	Altered Intestinal Function in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1561-1569.	2.8	499
14	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 1169-1186.	7.1	490
15	Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). <i>European Heart Journal</i> , 2013, 34, 512-519.	2.2	472
16	Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. <i>Lancet</i> , The, 2018, 392, 1047-1057.	13.7	467
17	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	7.1	434
18	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet</i> , The, 2020, 396, 1895-1904.	13.7	425

#	ARTICLE	IF	CITATIONS
19	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. <i>Circulation</i> , 2019, 139, 1289-1299.	1.6	384
20	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. <i>European Heart Journal</i> , 2020, 41, 1810-1817.	2.2	381
21	Ethical guidelines for publishing in the <i>Journal of Cachexia, Sarcopenia and Muscle</i> : update 2019. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1143-1145.	7.3	341
22	How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. <i>International Journal of Cardiology</i> , 2002, 86, 123-130.	1.7	335
23	Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. <i>New England Journal of Medicine</i> , 2019, 380, 447-458.	27.0	321
24	Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. <i>European Heart Journal</i> , 2013, 34, 816-829.	2.2	304
25	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014, 35, 2797-2815.	2.2	304
26	Ethical guidelines for publishing in the <i>Journal of Cachexia, Sarcopenia and Muscle</i> : update 2021. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 2259-2261.	7.3	302
27	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , 2017, 136, 1374-1383.	1.6	289
28	Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. <i>New England Journal of Medicine</i> , 2018, 379, 1332-1342.	27.0	265
29	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 1956-1964.	27.0	257
30	The syndrome of cardiac cachexia. <i>International Journal of Cardiology</i> , 2002, 85, 51-66.	1.7	248
31	Muscle wasting and cachexia in heart failure: mechanisms and therapies. <i>Nature Reviews Cardiology</i> , 2017, 14, 323-341.	13.7	243
32	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	5.2	232
33	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 553-576.	7.1	224
34	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 827-843.	7.1	223
35	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 326-336.	1.6	222
36	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. <i>Circulation</i> , 2021, 143, 337-349.	1.6	217

#	ARTICLE	IF	CITATIONS
37	Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial. <i>Lancet, The</i> , 2020, 396, 1353-1361.	13.7	209
38	Evaluation of the effects of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1279-1287.	7.1	205
39	Iron Deficiency in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 36-46.	4.1	195
40	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021, 144, 1284-1294.	1.6	195
41	ESC e-Cardiology Working Group Position Paper: Overcoming challenges in digital health implementation in cardiovascular medicine. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1166-1177.	1.8	194
42	Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Heart Journal</i> , 2018, 39, 4277-4284.	2.2	189
43	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 627-634.	7.1	183
44	Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2012, 157, 80-85.	1.7	180
45	Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. <i>Nature Reviews Cardiology</i> , 2011, 8, 485-493.	13.7	175
46	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Circulation</i> , 2021, 143, 540-552.	1.6	171
47	Muscle wasting and sarcopenia in heart failure and beyond: update 2017. <i>ESC Heart Failure</i> , 2017, 4, 492-498.	3.1	168
48	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. <i>Circulation</i> , 2021, 143, 310-321.	1.6	168
49	Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 1684-1691.	2.2	165
50	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 872-881.	7.1	160
51	Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 1326-1334.	7.1	156
52	Evaluation of the effect of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	7.1	155
53	A systems Biology Study to Tailored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIostat-CHF. <i>European Journal of Heart Failure</i> , 2016, 18, 716-726.	7.1	149
54	COVID-19: a major cause of cachexia and sarcopenia?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 863-865.	7.3	145

#	ARTICLE	IF	CITATIONS
55	Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1299-1305.	7.1	144
56	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , 2022, 43, 416-424.	2.2	144
57	Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). <i>European Journal of Heart Failure</i> , 2020, 22, 1891-1901.	7.1	142
58	Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). <i>European Journal of Heart Failure</i> , 2018, 20, 1580-1587.	7.1	139
59	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 196-213.	7.1	131
60	Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. <i>European Journal of Heart Failure</i> , 2018, 20, 199-215.	7.1	128
61	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	3.9	117
62	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	2.2	117
63	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.	2.2	114
64	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 180-188.	3.0	113
65	Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 22-34.	7.3	113
66	Trends in 30- and 90-Day Readmission Rates for Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008335.	3.9	113
67	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 333-344.	3.1	112
68	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients "who is doing what to whom and how?". <i>European Journal of Heart Failure</i> , 2018, 20, 1039-1051.	7.1	107
69	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193.	1.6	106
70	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1397-1407.	2.8	105
71	Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. <i>European Journal of Heart Failure</i> , 2021, 23, 854-871.	7.1	105
72	Muscle wasting disease: a proposal for a new disease classification. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014, 5, 1-3.	7.3	99

#	ARTICLE	IF	CITATIONS
73	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 671-680.	2.2	96
74	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 941-956.	7.1	95
75	Abnormalities of Potassium in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2836-2850.	2.8	94
76	Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1381-1392.	2.8	94
77	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 2272-2289.	7.1	92
78	Statin use and survival in patients with chronic heart failure – results from two observational studies with 5200 patients. <i>International Journal of Cardiology</i> , 2006, 112, 234-242.	1.7	90
79	Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project). <i>BMJ</i> , The, 2022, 377, e068788.	6.0	90
80	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 225-237.	6.1	89
81	Body composition changes in patients with systolic heart failure treated with beta blockers: A pilot study. <i>International Journal of Cardiology</i> , 2006, 106, 319-322.	1.7	88
82	Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. <i>Journal of the American College of Cardiology</i> , 2020, 75, 245-254.	2.8	88
83	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019, 21, 921-929.	7.1	86
84	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. <i>Circulation</i> , 2022, 145, 437-447.	1.6	86
85	Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. <i>European Heart Journal</i> , 2009, 30, 1331-1339.	2.2	85
86	Waist-to-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1269-1277.	7.1	85
87	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1378-1389.	7.1	83
88	Catabolic Signaling and Muscle Wasting After Acute Ischemic Stroke in Mice. <i>Stroke</i> , 2014, 45, 3675-3683.	2.0	79
89	Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the intervention. <i>European Journal of Heart Failure</i> , 2018, 20, 1485-1493.	7.1	76
90	Muscle wasting as an independent predictor of survival in patients with chronic heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1242-1249.	7.3	76

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Failure, 2020, 7, 3298-3309.	3.1	76
92	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clinical Research in Cardiology, 2020, 109, 1079-1098.	3.3	74
93	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. Journal of the American College of Cardiology, 2021, 78, 142-152.	2.8	74
94	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney International Reports, 2022, 7, 36-45.	0.8	73
95	Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 999-1005.	7.1	71
96	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European Heart Journal, 2021, 42, 3011-3020.	2.2	71
97	Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. European Heart Journal, 2019, 40, 3616-3625.	2.2	69
98	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal, 2019, 40, 3593-3602.	2.2	69
99	Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2019, 21, 1103-1113.	7.1	69
100	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. European Journal of Heart Failure, 2019, 21, 877-886.	7.1	68
101	Trends in prevalence of comorbidities in heart failure clinical trials. European Journal of Heart Failure, 2020, 22, 1032-1042.	7.1	68
102	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. European Journal of Heart Failure, 2020, 22, 126-135.	7.1	67
103	Sodium-glucose cotransporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441.	7.1	67
104	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	2.2	65
105	Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial. European Journal of Heart Failure, 2019, 21, 1012-1021.	7.1	64
106	Bioadrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. European Journal of Heart Failure, 2019, 21, 732-743.	7.1	64
107	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. Circulation, 2020, 142, 1205-1218.	1.6	63
108	Anaemia, iron deficiency and heart failure in 2020: facts and numbers. ESC Heart Failure, 2020, 7, 2007-2011.	3.1	63



#	ARTICLE	IF	CITATIONS
109	Detection of muscle wasting in patients with chronic heart failure using <i>C</i>-terminal agrin fragment: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (<sc>SICA-HF</sc>). European Journal of Heart Failure, 2015, 17, 1283-1293.	7.1	61
110	In-hospital worsening heart failure. European Journal of Heart Failure, 2015, 17, 1104-1113.	7.1	60
111	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. Journal of Cardiac Failure, 2014, 20, 319-326.	1.7	57
112	Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 1118-1127.	6.1	55
113	Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. Journal of the American College of Cardiology, 2021, 78, 1321-1332.	2.8	55
114	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. Journal of the American College of Cardiology, 2021, 78, 1337-1348.	2.8	52
115	Sarcopenia and Endothelial Function in Patients With Chronic Heart Failure: Results From the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). Journal of the American Medical Directors Association, 2017, 18, 240-245.	2.5	51
116	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrology Dialysis Transplantation, 2022, 37, 1014-1023.	0.7	50
117	Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results. JAMA Network Open, 2020, 3, e2012469.	5.9	50
118	Device Therapy in Chronic Heart Failure. Journal of the American College of Cardiology, 2021, 78, 931-956.	2.8	50
119	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction—insights from the <sc>ESC-HFA EORP</sc> Heart Failure Long-Term Registry. European Journal of Heart Failure, 2022, 24, 335-350.	7.1	49
120	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 181-195.	7.1	47
121	Cardiovascular implications of COVID-19 versus influenza infection: a review. BMC Medicine, 2020, 18, 403.	5.5	47
122	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	46
123	Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. Journal of Cardiac Failure, 2020, 26, 429-437.	1.7	46
124	One-year results of the first-in-man study investigating the <sc>Atrial Flow Regulator</sc> for left atrial shunting in symptomatic heart failure patients: the <sc>PRELIEVE</sc> study. European Journal of Heart Failure, 2021, 23, 800-810.	7.1	46
125	SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials. ESC Heart Failure, 2021, 8, 4693-4700.	3.1	45
126	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-HF study. European Journal of Heart Failure, 2019, 21, 112-120.	7.1	44



#	ARTICLE	IF	CITATIONS
127	Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2019, 4, 696.	6.1	43
128	Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. <i>Archives of Medical Science</i> , 2018, 14, 890-909.	0.9	42
129	Rationale and design of the AFFIRM <sup>2</sup> AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1651-1658.	7.1	42
130	Cardiac Cachexia Revisited. <i>Heart Failure Clinics</i> , 2020, 16, 61-69.	2.1	42
131	Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 1844-1854.	7.1	42
132	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 949-959.	11.4	41
133	Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1 RA treatment: A subgroup analysis from the FIDELIO <sup>2</sup> DKD trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 125-134.	4.4	41
134	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2058-2068.	2.8	41
135	Cardiac cachexia is associated with right ventricular failure and liver dysfunction. <i>International Journal of Cardiology</i> , 2013, 169, 219-224.	1.7	40
136	Rationale and design of the EMPERIAL <sup>2</sup> Preserved and EMPERIAL <sup>2</sup> Reduced trials of empagliflozin in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 932-942.	7.1	40
137	Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2893-2904.	2.8	39
138	Prognostic impact of muscle and fat mass in patients with heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 568-576.	7.3	39
139	Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. <i>European Heart Journal</i> , 2022, 43, 3435-3446.	2.2	39
140	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4442-4451.	2.2	38
141	Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). <i>Clinical Research in Cardiology</i> , 2018, 107, 991-1002.	3.3	37
142	Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the Telemedical Interventional Monitoring in Heart Failure (TIM <sup>2</sup> HF) study. <i>European Journal of Heart Failure</i> , 2021, 23, 186-194.	7.1	37
143	Time is prognosis <sup>TM</sup> in heart failure: time to treatment initiation as a modifiable risk factor. <i>ESC Heart Failure</i> , 2021, 8, 4444-4453.	3.1	37
144	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC <sup>2</sup> ORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	7.1	36

#	ARTICLE	IF	CITATIONS
145	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1129-1137.	2.8	36
146	Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	7.1	35
147	Conduct of Clinical Trials in the Era of COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2368-2378.	2.8	35
148	Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1861-1871.	2.8	34
149	Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials. <i>Circulation</i> , 2021, 144, 1193-1195.	1.6	34
150	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1390-1398.	7.1	33
151	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3168-3179.	3.1	33
152	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4455-4464.	2.2	33
153	Impact of mitral regurgitation in patients with worsening heart failure: insights from <i>BIOSTAT-CHF</i> . <i>European Journal of Heart Failure</i> , 2021, 23, 1750-1758.	7.1	32
154	COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	7.1	32
155	Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the <i>DIAMOND</i> trial. <i>European Journal of Heart Failure</i> , 2022, 24, 230-238.	7.1	32
156	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1261-1269.	0.7	32
157	Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from <i>EMPEROR-Reduced</i> . <i>European Journal of Heart Failure</i> , 2022, 24, 708-715.	7.1	32
158	Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trial. <i>The Lancet Digital Health</i> , 2020, 2, e16-e24.	12.3	31
159	Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 260-267.	7.1	30
160	Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. <i>American Journal of Nephrology</i> , 2018, 48, 260-268.	3.1	30
161	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the <i>EMPEROR-Reduced</i> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1529-1538.	7.1	30
162	Empagliflozin and serum potassium in heart failure: an analysis from <i>EMPEROR-Pooled</i> . <i>European Heart Journal</i> , 2022, 43, 2984-2993.	2.2	30

#	ARTICLE	IF	CITATIONS
163	Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. <i>Journal of Cardiac Failure</i> , 2021, 27, 727-743.	1.7	29
164	Effects of hormonal changes on sarcopenia in chronic kidney disease: where are we now and what can we do?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1380-1392.	7.3	29
165	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 35-45.	11.4	29
166	Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle. <i>ESC Heart Failure</i> , 2018, 5, 549-551.	3.1	28
167	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , 2020, 109, 331-338.	3.3	28
168	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , 2020, 22, 70-80.	7.1	28
169	A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 821-833.	7.1	28
170	Heart failure as a metabolic problem. <i>European Journal of Heart Failure</i> , 1999, 1, 127-131.	7.1	26
171	Cognitive Decline Over Time in Patients With Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 1042-1053.	4.1	26
172	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. <i>European Journal of Heart Failure</i> , 2021, 23, 567-577.	7.1	26
173	Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2022, 24, 245-248.	7.1	26
174	Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis. <i>European Journal of Heart Failure</i> , 2019, 21, 1291-1294.	7.1	25
175	Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review. <i>Nutrients</i> , 2021, 13, 257.	4.1	24
176	Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1219-1227.	7.1	23
177	Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005544.	3.9	23
178	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. <i>European Journal of Heart Failure</i> , 2020, 22, 2175-2186.	7.1	23
179	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. <i>ESC Heart Failure</i> , 2020, 7, 2098-2112.	3.1	23
180	Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. <i>Cardiovascular Research</i> , 2022, 118, 2231-2252.	3.8	23



#	ARTICLE	IF	CITATIONS
199	Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in <scp>EMPEROR</scp> Reduced</scp>. European Journal of Heart Failure, 2022, 24, 1829-1839.	7.1	19
200	Biomarker guidance allows a more personalized allocation of patients for remote patient management in heart failure: results from the TIM&#x2013;CHF2 trial. European Journal of Heart Failure, 2019, 21, 1445-1458.	7.1	18
201	A tissue&#x2013;specific screen of ceramide expression in aged mice identifies ceramide synthase&#x2013;1 and ceramide synthase&#x2013;5 as potential regulators of fiber size and strength in skeletal muscle. Aging Cell, 2020, 19, e13049.	6.7	18
202	Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. European Journal of Internal Medicine, 2021, 89, 65-75.	2.2	18
203	Head&#x2013;to&#x2013;head comparison between recommendations by the <scp>ESC</scp> and <scp>ACC</scp>/<scp>AHA</scp>/<scp>HFSA</scp> heart failure guidelines. European Journal of Heart Failure, 2022, 24, 916-926.	7.1	18
204	Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. European Journal of Clinical Pharmacology, 2016, 72, 813-822.	1.9	17
205	Similar clinical benefits from below&#x2013;target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. European Journal of Heart Failure, 2018, 20, 359-369.	7.1	17
206	Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart&#x2013;Failure. Journal of the American College of Cardiology, 2021, 77, 2432-2447.	2.8	17
207	Dronedaron for the Treatment of Atrial Fibrillation with Concomitant Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Post&#x2013;Hoc Analysis of the ATHENA Trial. European Journal of Heart Failure, 2022, , .	7.1	17
208	A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure. Nutrients, 2020, 12, 2541.	4.1	16
209	Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST&#x2013;WHF in perspective. ESC Heart Failure, 2020, 7, 3261-3267.	3.1	16
210	A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 846-851.	0.6	15
211	Genetic risk and atrial fibrillation in patients with heart failure. European Journal of Heart Failure, 2020, 22, 519-527.	7.1	15
212	Cardiovascular and non&#x2013;cardiovascular death distinction: the utility of troponin beyond N&#x2013;terminal pro&#x2013;B&#x2013;type natriuretic peptide. Findings from the BIOSTAT&#x2013;CHF study. European Journal of Heart Failure, 2020, 22, 81-89.	7.1	15
213	Standardized Definitions for Evaluation&#x2013;of&#x2013;Heart Failure Therapies: Scientific Expert Panel From the Heart&#x2013;Failure Collaboratory and Academic Research Consortium. JACC: Heart Failure, 2020, 8, 961-972.	4.1	15
214	The value of spot urinary creatinine as a marker of muscle wasting in patients with new&#x2013;onset or worsening heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 555-567.	7.3	15
215	Non&#x2013;adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography&#x2013;tandem mass spectrometry (results of a prospective) Tj ETQq1 1 0.784317.rgBT /Overlock 10		
216	Remote Speech Analysis in the Evaluation of Hospitalized Patients With Acute Decompensated Heart&#x2013;Failure. JACC: Heart Failure, 2022, 10, 41-49.	4.1	15

#	ARTICLE	IF	CITATIONS
217	The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 662-674.	4.4	15
218	Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, 24, 821-832.	7.1	15
219	Cardiac expression of neutrophil gelatinase-associated lipocalin in a model of cancer cachexia-induced cardiomyopathy. <i>ESC Heart Failure</i> , 2019, 6, 89-97.	3.1	14
220	Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial. <i>JACC: Heart Failure</i> , 2020, 8, 359-368.	4.1	14
221	Assessment of coronary artery disease during hospitalization for cancer treatment. <i>Clinical Research in Cardiology</i> , 2021, 110, 200-210.	3.3	14
222	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 888-895.	1.7	14
223	Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 1960-1970.	7.1	14
224	A population-based study of 92 clinically recognized risk factors for heart failure: co-occurrence, prognosis and preventive potential. <i>European Journal of Heart Failure</i> , 2022, 24, 466-480.	7.1	14
225	Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions. <i>European Journal of Heart Failure</i> , 2022, 24, 1400-1405.	7.1	14
226	Advanced cancer is also a heart failure syndrome: a hypothesis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 533-537.	7.3	13
227	Iron Deficiency in CKD Without Concomitant Anemia. <i>Kidney International Reports</i> , 2021, 6, 2752-2762.	0.8	13
228	Sympatho-Vagal Imbalance is Associated with Sarcopenia in Male Patients with Heart Failure. <i>Arquivos Brasileiros De Cardiologia</i> , 2019, 112, 739-746.	0.8	13
229	Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 372-383.	0.7	13
230	Defects in insulin action in chronic heart failure. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 203-212.	4.4	12
231	Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?. <i>European Journal of Heart Failure</i> , 2022, 24, 1460-1466.	7.1	12
232	Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. <i>ESC Heart Failure</i> , 2021, 8, 16-25.	3.1	11
233	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. <i>European Heart Journal</i> , 2021, 42, 4887-4890.	2.2	11
234	Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2021, 23, 1170-1181.	7.1	11



#	ARTICLE	IF	CITATIONS
235	Left ventricular dimensions and cardiovascular outcomes in systolic heart failure: the WARCEF trial. ESC Heart Failure, 2021, 8, 4997-5009.	3.1	11
236	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. Clinical Research in Cardiology, 2019, 108, 797-805.	3.3	10
237	The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARMACHF randomized controlled trial. ESC Heart Failure, 2020, 7, 3310-3319.	3.1	10
238	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. ESC Heart Failure, 2021, 8, 4425-4443.	3.1	10
239	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clinical Research in Cardiology, 2022, 111, 912-923.	3.3	10
240	Distinct pathophysiological pathways in women and men with heart failure. European Journal of Heart Failure, 2022, 24, 1532-1544.	7.1	10
241	Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis. European Journal of Heart Failure, 2022, 24, 1625-1632.	7.1	10
242	Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. ESC Heart Failure, 2020, 7, 953-963.	3.1	9
243	Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure. European Journal of Heart Failure, 2021, 23, 947-953.	7.1	9
244	Sarcopenia in patients after an episode of acute decompensated heart failure: An underdiagnosed problem with serious impact. Clinical Nutrition, 2021, 40, 4490-4499.	5.0	9
245	Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. JACC: Heart Failure, 2021, 9, 518-527.	4.1	9
246	Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature. ESC Heart Failure, 2021, 8, 4717-4736.	3.1	9
247	Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. European Journal of Heart Failure, 2022, 24, 308-320.	7.1	9
248	Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF. JACC: Heart Failure, 2022, 10, 651-661.	4.1	9
249	Obesity and risk of myocardial infarction: the INTERHEART study. Lancet, The, 2006, 367, 1051-1052.	13.7	8
250	Beta blockers and glucose metabolism in chronic heart failure: Friend or foe?. Clinical Research in Cardiology, 2008, 97, 21-23.	3.3	8
251	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. Cardiovascular Research, 2021, 117, 2228-2236.	3.8	8
252	Hypokalaemia and outcomes in older patients hospitalized for heart failure. ESC Heart Failure, 2020, 7, 794-803.	3.1	8



#	ARTICLE	IF	CITATIONS
253	Adherence to ESC cardiac resynchronization therapy guidelines: findings from the ESC CRT Survey II. <i>Europace</i> , 2020, 22, 932-938.	1.7	8
254	Safety and efficacy of iron supplementation after myocardial infarction in mice with moderate blood loss anaemia. <i>ESC Heart Failure</i> , 2021, 8, 5445-5455.	3.1	8
255	Responder analysis for improvement in six-minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, , .	7.1	8
256	Kidney function assessment and endpoint ascertainment in clinical trials. <i>European Heart Journal</i> , 2022, 43, 1379-1400.	2.2	8
257	Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 2131-2139.	7.1	8
258	Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 675-680.	7.3	7
259	Heart failure prevalence in the general population: SOBOTA-HF study rationale and design. <i>ESC Heart Failure</i> , 2019, 6, 1077-1084.	3.1	7
260	Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial. <i>ESC Heart Failure</i> , 2019, 6, 297-307.	3.1	7
261	Implications of serial measurements of natriuretic peptides in heart failure: insights from <sc>BIOSTAT-HF</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 1486-1490.	7.1	7
262	High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. <i>Cardiovascular Research</i> , 2023, 119, 213-220.	3.8	7
263	Feasibility of remote speech analysis in evaluation of dynamic fluid overload in heart failure patients undergoing haemodialysis treatment. <i>ESC Heart Failure</i> , 2021, 8, 2467-2472.	3.1	7
264	Percutaneous Mitral Valve Annuloplasty in Patients With Secondary Mitral Regurgitation and Severe Left Ventricular Enlargement. <i>JACC: Heart Failure</i> , 2021, 9, 453-462.	4.1	7
265	Response by Filippatos et al to Letter Regarding Article, "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes". <i>Circulation</i> , 2021, 144, e202-e203.	1.6	7
266	Clinical implications of low estimated protein intake in patients with heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, , .	7.3	7
267	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , 2018, 15, 35.	2.1	6
268	The Obesity Paradigm and Lifetime Risk of Cardiovascular Disease. <i>JAMA Cardiology</i> , 2018, 3, 895.	6.1	6
269	New treatments for hyperkalaemia: clinical use in cardiology. <i>European Heart Journal Supplements</i> , 2019, 21, A41-A47.	0.1	6
270	Ten lessons from the <sc>EMPEROR-Reduced</sc> trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1991-1993.	7.1	6

#	ARTICLE	IF	CITATIONS
271	Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas disease and other aetiologies. ESC Heart Failure, 2020, 7, 3086-3094.	3.1	6
272	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. ESC Heart Failure, 2021, 8, 26-36.	3.1	6
273	Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights. European Heart Journal, 2022, 43, 2968-2970.	2.2	6
274	Impact of Geographic Region on the COMMANDER-HF Trial. JACC: Heart Failure, 2021, 9, 201-211.	4.1	6
275	Effect of Carillon Mitral Contour System on patient-reported outcomes in functional mitral regurgitation: an individual participant data meta-analysis. ESC Heart Failure, 2021, 8, 1885-1891.	3.1	6
276	Exercise for Frail, Elderly Patients with Acute Heart Failure – A Strong Step Forward. New England Journal of Medicine, 2021, 385, 276-277.	27.0	6
277	Education and certification on heart failure of the Heart Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 249-253.	7.1	6
278	Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure. European Journal of Heart Failure, 2020, 22, 906-910.	7.1	5
279	Telomere length is independently associated with all-cause mortality in chronic heart failure. Heart, 2022, 108, 124-129.	2.9	5
280	Spontaneous Non-Sustained Ventricular Tachycardia and Premature Ventricular Contractions and Their Prognostic Relevance in Patients with Cancer in Routine Care. Cancers, 2021, 13, 2303.	3.7	5
281	Can we trust a smartwatch ECG? Potential and limitations. European Journal of Heart Failure, 2021, 23, 850-853.	7.1	5
282	Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. Circulation, 2021, 144, 1265-1267.	1.6	5
283	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. ESC Heart Failure, 2021, 8, 4394-4408.	3.1	5
284	Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovascular Research, 2022, 118, 2478-2487.	3.8	5
285	Prognostic impact of 6-min walk test distance in patients with systolic heart failure: insights from the WARCEF trial. ESC Heart Failure, 2021, 8, 819-828.	3.1	5
286	Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease. Diabetes Research and Clinical Practice, 2022, 186, 109837.	2.8	5
287	Surrogate markers of gut dysfunction are related to heart failure severity and outcome from the BIOSTAT-CHF consortium. American Heart Journal, 2022, 248, 108-119.	2.7	5
288	Cardiac Cachexia Revisited. Cardiology Clinics, 2022, 40, 199-207.	2.2	5

#	ARTICLE	IF	CITATIONS
289	Vasodilation and Exercise Capacity in Patients with End-Stage Renal Disease: A Prospective Proof-of-Concept Study. <i>CardioRenal Medicine</i> , 2017, 7, 50-59.	1.9	4
290	The evolving obesity paradigm story: from heart failure to atrial fibrillation. <i>European Heart Journal</i> , 2019, 40, 1550-1552.	2.2	4
291	Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring. <i>ESC Heart Failure</i> , 2021, , .	3.1	4
292	Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure. <i>ESC Heart Failure</i> , 2022, , .	3.1	4
293	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 228-239.	4.5	4
294	Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2107-2118.	3.1	4
295	Therapeutic patents for chronic heart failure: a review of patent applications from 1996 to 2002. <i>Expert Opinion on Therapeutic Patents</i> , 2004, 14, 639-654.	5.0	3
296	More variety with the <i>Journal of Cachexia, Sarcopenia and Muscle</i> : <i>JCSM Clinical Reports</i> and <i>JCSM Rapid Communications</i> have both gone live. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 217-219.	7.3	3
297	Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). <i>American Journal of Cardiology</i> , 2018, 122, 821-827.	1.6	3
298	The <i>Journal of Cachexia, Sarcopenia and Muscle</i> stays the front-runner in geriatrics and gerontology. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1151.	7.3	3
299	Acute effects of oral triglyceride load on dynamic changes in peripheral endothelial function in heart failure patients with reduced ejection fraction and healthy controls. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1961-1966.	2.6	3
300	Extra-cardiac targets in the management of cardiometabolic disease: Device-based therapies. <i>ESC Heart Failure</i> , 2021, 8, 3327-3338.	3.1	3
301	Major Depression and Anxiety Among Patients Hospitalized With Heart Failure. <i>American Journal of Cardiology</i> , 2021, 142, 153-155.	1.6	2
302	FC 090EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	2
303	Novel biomarkers in heart failure and cardio-oncology. <i>Kardiologia Polska</i> , 2019, 77, 329-330.	0.6	2
304	Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients. <i>NDT Plus</i> , 2009, 2, i3-i8.	0.2	1
305	Once I get on a puzzle, I can't get off: Cachexia and wasting in 2018. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1021-1022.	7.3	1
306	The <i>Journal of Cachexia, Sarcopenia and Muscle</i> in 2019. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 715-720.	7.3	1

#	ARTICLE	IF	CITATIONS
307	Trends in prevalence of comorbidities in heart failure clinical trials. , 2020, 22, 1032.		1
308	The (apparent) sacubitril/valsartan sex interaction in heart failure with preserved ejection fraction: not the result of relaxin effects but of BNP action?!. ESC Heart Failure, 2020, 7, 3274-3277.	3.1	1
309	Corrigendum to "Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure" [European Journal of Heart Failure 5 (2003) 609-614]. European Journal of Heart Failure, 2004, 6, 245-245.	7.1	0
310	The new Heart Failure Association journal " ESC Heart Failure. European Journal of Heart Failure, 2018, 20, 1657-1663.	7.1	0
311	Open access efforts begin to bloom: ESC Heart Failure gets full attention and first impact factor. ESC Heart Failure, 2019, 6, 903-908.	3.1	0
312	Creating an impact, not an impression: ESC Heart Failure in its seventh year. ESC Heart Failure, 2021, 8, 3451-3452.	3.1	0
313	Abstract 14960: Empagliflozin Reduces the Total Burden of Cardiovascular Events Including Recurrent Events in the EMPA-REG OUTCOME Trial. Circulation, 2020, 142, .	1.6	0
314	MO198: Outcomes with Finerenone in Patients with Stage 4 Chronic Kidney Disease and Type 2 Diabetes: A Fidelity Subgroup Analysis. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0